---
schema_version: "secwatch.filing_event.v1"
accession: "0001835567-22-000073"
form_type: "8-K"
ticker: null
cik: "0001835567"
company_name: "Pear Therapeutics, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T21:12:54.700135+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pear Therapeutics Q3 revenue $4.1M, +24% QoQ; cuts 22% workforce

## Summary
- Revenue $4.1M in Q3 2022, up 24% from Q2 2022 and 211% vs Q3 2021.
- Workforce reduced by ~59 employees (22% of total); expects $2.6M cash severance costs in Q4 2022.
- Annual cash cost savings from workforce reduction estimated at $10.7M.
- 2022 revenue guidance reaffirmed at $14-16M; 2023 revenue guidance set at $27-37M.
- Key operating metrics: prescriptions 11,400+, fulfillment rate 60%, payment rate 49%, ASP $1,345.

## SEC filing metadata
- accession: 0001835567-22-000073
- form_type: 8-K
- cik: 0001835567
- company_name: Pear Therapeutics, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835567/000183556722000073/0001835567-22-000073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835567/000183556722000073/pear-20221114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001835567-22-000073
- JSON: https://secwatch.observer/filing/0001835567-22-000073.json
- Plain text: https://secwatch.observer/filing/0001835567-22-000073.txt

## Key facts
- Earnings Releases
  Pear Therapeutics, Inc. reported Full Year 2023 results: revenue $27 million to $37 million. Guidance initiated.
  - Period: Full Year 2023
  - Revenue: $27 million to $37 million
  - Guidance: initiated
  - Result: guidance update
  source text: Pear expects 2023 revenue in the range of $27 million to $37 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835567/000183556722000073/0001835567-22-000073-index.htm
- Earnings Releases
  Pear Therapeutics, Inc. reported Full Year 2022 results: revenue $14-16 million. Guidance reaffirmed.
  - Period: Full Year 2022
  - Revenue: $14-16 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02. Results of Operations and Financial Condition. On November 14, 2022, Pear Therapeutics, Inc. (the "Company") issued a press release reporting the financial results of the Company for the third quarter ended September 30, 2022 and other
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835567/000183556722000073/0001835567-22-000073-index.htm
- Restructurings & Charges
  Pear Therapeutics, Inc. announced a restructuring with charges of approximately $2.6 million of cash based expenses related to employee severance, benefits, and related costs, and a stock-based compensation charge of between $ affecting workforce (approximately 59 employees).
  - Type: restructuring
  - Charge: approximately $2.6 million of cash based expenses related to employee severance, benefits, and related costs, and a stock-based compensation charge of between $
  - Affected area: workforce
  - Headcount: approximately 59 employees
  source text: On November 14, 2022, due to the worsening macroeconomic environment, the Board of Directors of the Company approved a reduction in the Company's workforce by approximately 59 employees, representing approximately 22% of the Company's total workforce as of September 30, 2022. The reduction in workforce is intended to reduce operating expenses. In connection with the reduction in force, the Company estimates it will incur approximately $2.6 million of cash based expenses related to employee severance, benefits, and related costs, primarily in the fourth quarter of 2022, when it anticipates that the reduction in workforce will be substantially complete. In addition, the Company expects to record a stock-based compensation charge of between $0.3 million and $0.9 million and corresponding payroll tax expense related to modifications of equity awards for employees impacted by the reduction in workforce, subject to local law and consultation requirements, which could extend the process into
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835567/000183556722000073/0001835567-22-000073-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.